Core Laboratories (NYSE:CLB) Lowered to Sell Rating by Wall Street Zen

Core Laboratories (NYSE:CLB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded shares of Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Core Laboratories has an average rating of “Reduce” and a consensus price target of $12.00.

Core Laboratories Stock Up 0.3%

NYSE CLB opened at $11.49 on Friday. The stock’s 50 day moving average is $13.37 and its 200 day moving average is $16.03. The company has a current ratio of 2.05, a quick ratio of 1.50 and a debt-to-equity ratio of 0.42. Core Laboratories has a 12 month low of $9.72 and a 12 month high of $20.36. The stock has a market cap of $529.92 million, a PE ratio of 17.68, a P/E/G ratio of 2.21 and a beta of 1.00.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, April 29th. The oil and gas company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. Core Laboratories had a return on equity of 11.52% and a net margin of 5.94%.The business had revenue of $121.80 million during the quarter, compared to the consensus estimate of $122.99 million. During the same period in the prior year, the company posted $0.14 EPS. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS. Research analysts predict that Core Laboratories will post 0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Core Laboratories

A number of hedge funds have recently made changes to their positions in CLB. Summit Securities Group LLC bought a new position in Core Laboratories during the first quarter valued at approximately $31,000. Aster Capital Management DIFC Ltd bought a new stake in Core Laboratories in the 4th quarter worth approximately $34,000. Quarry LP raised its holdings in shares of Core Laboratories by 118.1% during the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock worth $36,000 after acquiring an additional 1,599 shares in the last quarter. CWM LLC raised its holdings in shares of Core Laboratories by 36.1% during the 4th quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock worth $40,000 after acquiring an additional 668 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in shares of Core Laboratories by 124.7% during the 4th quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company’s stock valued at $51,000 after acquiring an additional 1,763 shares during the last quarter. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.